Anzeige
Mehr »
Login
Sonntag, 09.08.2020 Börsentäglich über 12.000 News von 643 internationalen Medien
NEU! Unglaublich, aber wahr! Bis zu 1.000% mit dieser Gold-Kupfer-Aktie! Das ist Ihr nächstes Millionen-Los!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DNTB ISIN: CH0346177709 Ticker-Symbol: 22D 
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
OBSEVA SA Chart 1 Jahr
5-Tage-Chart
OBSEVA SA 5-Tage-Chart
GlobeNewswire (Europe)
233 Leser
Artikel bewerten:
(2)

ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020

Geneva, Switzerland and Boston, MA - July 15, 2020 - ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced winning the Clinical Science Award for Oral Presentation at the ESHRE Virtual 36th Annual Meeting, which took place July 5-8, 2020. The Award was presented to the first and presenting author of the best oral presentation on a clinical science topic.

Dr Hugh Taylor, presented on Monday, July 6th, from 11:00 - 11:10 CEST in Session 05

Presentation number: O-190

Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial

The link for the presentation on the ESHRE platform, is available under "Events Calendar"

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol "OBSN". For more information, please visit www.ObsEva.com.

About Linzagolix

Linzagolix is a novel, once daily, oral GnRH receptor antagonist with a potentially best-in-class profile. Linzagolix is currently in late-stage clinical development for the treatment of heavy menstrual bleeding associated with uterine fibroids and pain associated with endometriosis. ObsEva licensed linzagolix from Kissei in late 2015 and retains worldwide commercial rights, excluding Asia, for the product.

About Kissei

Kissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia, which is sold worldwide through its licensees. KLH-2109/OBE2109 is a new chemical entity discovered by Kissei R&D.

For further information, please contact:

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com

+1 857 972 9347 Office
+1 781 366 5726 Mobile

Attachment

  • Press Release in Pdf (https://ml-eu.globenewswire.com/Resource/Download/6221191d-8f60-4c46-b4f0-0196f53570d8)
OBSEVA-Aktie komplett kostenlos handeln - auf Smartbroker.de
© 2020 GlobeNewswire (Europe)
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.